CSLLY Overview
Upcoming Projects (CSLLY)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (CSLLY)
-
A Second Look: Exploring the recent FDA approval of DAWNZERA (donidalorsen) from Ionis Pharmaceuticals and ANDEMBRY® (garadacimab-gxii) from CSL for patients with hereditary angioedema
Tickers: IONS, CSLLY
Executed On: Sep 25, 2025 at 05:00 PM EDT -
Exploring the recent FDA approval of DAWNZERA (donidalorsen) from Ionis Pharmaceuticals and ANDEMBRY® (garadacimab-gxii) from CSL for patients with hereditary angioedema
Tickers: IONS, CSLLY
Executed On: Sep 24, 2025 at 02:00 PM EDT -
Exploring the current treatment landscape for Hemophilia A & B, including CSL Behring's Hemgenix (etranacogene dezaparvovec-drlb) and Biomarin's potential gene therapy ROCTAVIAN (valoctocogene roxaparvovec)
Tickers: BMRN, CSLLY, QURE
Executed On: Apr 25, 2023 at 09:00 AM EDT
Upcoming & Overdue Catalysts (CSLLY)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (CSLLY)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
